BIO-Europe Spring Presenting Companies 2023
EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on enhancement of epithelial barrier integrity as a critical pathophysiological factor underlying the etiology of a number of major diseases. Epithelial cells are a key component of the barrier that makes up human lung tissue and other organs such as the gut and skin. Compromised integrity of this barrier is implicated in the progression and non-resolution of several chronic inflammatory diseases. The EpiEndo proprietary portfolio of molecules are called Barriolides and aim to be first-in-class barrier enhancing therapeutics, to address the huge global burden of chronic diseases of the lung and other organs where there is significant unmet medical need. EpiEndo was founded in 2014 and has its headquarters and biology lab in Reykjavik, Iceland, and a chemistry lab close to Karolinska Institute in Stockholm, Sweden.